Spring brings beautiful weather, but with it also comes several potential hazards for dogs and cats. From toxic plants to ...

Hoth Therapeutics' shares surged more than 250% to $3 following positive interim results from its Phase 2a trial of HT-001, aimed at treating skin toxicities from EGFR inhibitors in cancer patients.